Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

52.21
+0.38000.73%
Post-market: 52.270.0600+0.11%19:52 EDT
Volume:2.67M
Turnover:140.72M
Market Cap:5.05B
PE:-10.97
High:53.67
Open:52.16
Low:51.83
Close:51.83
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:2.19
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:2.89
PE(LYR):-8.07

Loading ...

Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial

TIPRANKS
·
May 23

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
May 14

A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest

Simply Wall St.
·
May 12

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

TIPRANKS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83

TIPRANKS
·
May 05

CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated

TIPRANKS
·
May 05

CRISPR Therapeutics Ag : Bofa Global Research Cuts Price Objective to $83.00 From $86.00

THOMSON REUTERS
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeneDx Holdings (WGS) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Switzerland's CRISPR Therapeutics Q1 net loss narrows

Reuters
·
May 05

CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate

Benzinga Earnings
·
May 05

CRISPR Therapeutics Q1 net loss narrows to $122.9 million; revenue hits $43 million

Reuters
·
May 05

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 05

Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes

Dow Jones
·
Apr 29

Intellia Therapeutics Reports Positive Phase 3 Trial Results for CRISPR-Based Gene Therapy

Deep News
·
Apr 27

Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?

Simply Wall St.
·
Apr 24

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

GlobeNewswire
·
Apr 16